Key result
Extending lipid monitoring to 9-15 months in T2DM is linked to ~26% higher mortality risk.
Why the study?
Guidelines differ on how often to monitor lipid profiles in adults with T2DM without established CVD, and randomized evidence is lacking.
Does extending lipid monitoring intervals increase the risk of mortality or major CVD in adults with T2DM without prior CVD?
Observational
Yes
Does extending lipid monitoring intervals increase the risk of mortality or major CVD in adults with T2DM without prior CVD?
Lipid monitoring frequency in T2DM patients without prior CVD should be individualized based on baseline LDL-C levels, with more frequent monitoring (2-8 months) needed for those with LDL-C ≥ 2.6 mmol/L.
May support LDL-C–tailored monitoring intervals in T2DM; leaves open causal effects pending randomized trials.
BACKGROUND: Guidelines differ on how often to monitor lipid profiles in adults with type 2 diabetes mellitus (T2DM) without established cardiovascular disease (CVD), and randomized evidence is lacking. This study aimed to optimise lipid monitoring intervals for type-2 diabetes mellitus (T2DM) patients at various LDL-C levels. METHODS: This is a target trial emulation study using territory-wide electronic health records from the Hong Kong Hospital Authority. Adults with T2DM and no prior CVD who had ≥2 lipid panel tests within any 12‑month window during 2009-2012 were enrolled. The index date was the date of the second lipid test. Participants were stratified by baseline LDL‑C (<1.8, 1.8-2.59, ≥2.6 mmol/L). Within each LDL‑C stratum, we emulated a three-arm target trial using a clone-censor-weight (CCW) approach to compare three monitoring strategies: monitoring lipid panels every (1) 2-8 months, (2) 9-15 months, or (3) 16-24 months. Pooled logistic regression was used to estimate hazard ratios (HRs) for all‑cause mortality and major CVD associated with each monitoring strategy. Follow‑up continued until the first occurrence of an outcome, death, or 31 December 2021. RESULTS: For LDL-C < 1.8 mmol/L, extending monitoring intervals to 16-24 months were not associated with higher risks of mortality or CVD risk compared to 2-8 months (HR [95% CI]: mortality: 1.094 [0.948, 1.263]; CVD: 1.002 [0.846, 1.187]). For the group with LDL-C levels of 1.8-2.59 mmol/L, monitoring of the lipid profile every 16-24 months was associated with higher mortality risk compared to monitoring every 2-8 months (HR [95% CI]: 1.154 [1.069, 1.245]). For LDL-C ≥ 2.6 mmol/L, monitoring every 9-15 months was associated with higher risks of mortality and CVD compared to 2-8 months (HR [95% CI]: mortality: 1.263 [1.174, 1.359]; CVD: 1.060 [1.017, 1.105]). CONCLUSIONS: Lipid monitoring frequency in T2DM may be individualized by baseline LDL‑C level, with intervals of approximately 16-24, 9-15, and 2-8 months representing minimum frequencies.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted an observational in Type 2 diabetes mellitus without established cardiovascular disease. Lipid panel monitoring every 9-15 or 16-24 months vs. Lipid panel monitoring every 2-8 months was evaluated on All-cause mortality and major CVD (HR 1.263, 95% CI 1.174-1.359). Extending lipid monitoring to 9-15 months in T2DM patients with LDL-C ≥2.6 mmol/L increased mortality risk compared to 2-8 months (HR 1.263; 95% CI 1.174-1.359).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: